November 22nd 2024
Pediatric melanoma, though rare, is the deadliest skin cancer in children, with 300-500 US cases annually.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Topical tacrolimus clears peristomal PG
February 21st 2005Local treatment with the topical immunomodulator tacrolimus 0.1 percent ointment (Protopic, Fujisawa) may be a useful adjunct in the management of pyoderma gangrenosum (PG), and can some times be used successfully as monotherapy, perhaps particularly for the treatment of peristomal disease, said David Fivenson, M.D.
Palmoplantar pustulosis merits greater research attention
February 20th 2005Palmoplantar pustulosis (palmoplantar pustular psoriasis) presents a frustrating therapeutic challenge to clinicians and a disabling disease for patients deserving of greater research interest from the global dermatology community, says Robert J.G. Chalmers, M.B.B.S.
Palmoplantar pustulosis merits greater research attention
February 20th 2005Palmoplantar pustulosis (palmoplantar pustular psoriasis) presents a frustrating therapeutic challenge to clinicians and a disabling disease for patients deserving of greater research interest from the global dermatology community, says Robert J.G. Chalmers, M.B.B.S.